Xeris Pharma's liquid glucagon an Orphan Drug is Europe for rare insulin disorder

|About: Xeris Pharmaceuticals (XERS)|By:, SA News Editor

The European Medicines Agency designates Xeris Pharmaceuticals' (XERS -15.2%) ready-to-use liquid glucagon for the treatment of noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS), a rare metabolic disorder characterized by elevated levels of insulin in the blood and low blood glucose.

Post-gastric bypass hypoglycemia (low blood sugar) presents similar features but it considered a separate clinical entity.

Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.

Subscribe for full text news in your inbox